Current status and future directions in gastric cancer with peritoneal dissemination

Surg Oncol Clin N Am. 2012 Oct;21(4):625-33. doi: 10.1016/j.soc.2012.07.002. Epub 2012 Sep 4.

Abstract

Peritoneal carcinomatosis arising from gastric cancer is mostly associated with poor prognosis. Despite the improvement of survival with modern polychemotherapy, the results are still unsatisfactory. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy might provide an additional therapeutic option for highly selected patients with gastric cancer and peritoneal metastasis leading to improved prognosis. Considering the increased rate of perioperative morbidity and the crucial prognostic role of complete macroscopic cytoreduction, adequate preoperative diagnostics and patient selection are strongly recommended. Further prospective randomized trials are needed to determine the roles of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as part of an interdisciplinary treatment concept.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / administration & dosage*
  • Antineoplastic Agents / therapeutic use
  • Carcinoma / drug therapy
  • Carcinoma / secondary*
  • Carcinoma / surgery
  • Chemotherapy, Cancer, Regional Perfusion / methods*
  • Humans
  • Hyperthermia, Induced / methods*
  • Patient Selection
  • Peritoneal Neoplasms / drug therapy
  • Peritoneal Neoplasms / secondary*
  • Peritoneal Neoplasms / surgery
  • Peritoneum / pathology
  • Preoperative Care
  • Stomach Neoplasms / pathology*
  • Survival Analysis

Substances

  • Antineoplastic Agents